Kobayashi M - Search Results

1

Non-invasive high-risk screening for Fabry disease hemizygotes and heterozygotes.

Kitagawa T, Suzuki K, Ishige N, Ohashi T, Kobayashi M, Eto Y, Tanaka A, Odaka H, Owada M. Kitagawa T, et al. Among authors: kobayashi m. Pediatr Nephrol. 2008 Sep;23(9):1461-71. doi: 10.1007/s00467-008-0846-6. Epub 2008 Jun 6. Pediatr Nephrol. 2008. PMID: 18535844

2

Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry.

Kitagawa T, Ishige N, Suzuki K, Owada M, Ohashi T, Kobayashi M, Eto Y, Tanaka A, Mills K, Winchester B, Keutzer J. Kitagawa T, et al. Among authors: kobayashi m. Mol Genet Metab. 2005 Jul;85(3):196-202. doi: 10.1016/j.ymgme.2005.01.007. Epub 2005 Apr 26. Mol Genet Metab. 2005. PMID: 15979031

3

Significance of screening for Fabry disease among male dialysis patients.

Ichinose M, Nakayama M, Ohashi T, Utsunomiya Y, Kobayashi M, Eto Y. Ichinose M, et al. Among authors: kobayashi m. Clin Exp Nephrol. 2005 Sep;9(3):228-32. doi: 10.1007/s10157-005-0369-4. Clin Exp Nephrol. 2005. PMID: 16189631

4

Prevalence of Fabry disease in dialysis patients: Japan Fabry disease screening study (J-FAST).

Saito O, Kusano E, Akimoto T, Asano Y, Kitagawa T, Suzuki K, Ishige N, Akiba T, Saito A, Ishimura E, Hattori M, Hishida A, Guili C, Maruyama H, Kobayashi M, Ohashi T, Matsuda I, Eto Y. Saito O, et al. Among authors: kobayashi m. Clin Exp Nephrol. 2016 Apr;20(2):284-93. doi: 10.1007/s10157-015-1146-7. Epub 2015 Jul 22. Clin Exp Nephrol. 2016. PMID: 26197777

5

No accumulation of globotriaosylceramide in the heart of a patient with the E66Q mutation in the α-galactosidase A gene.

Kobayashi M, Ohashi T, Fukuda T, Yanagisawa T, Inomata T, Nagaoka T, Kitagawa T, Eto Y, Ida H, Kusano E. Kobayashi M, et al. Mol Genet Metab. 2012 Dec;107(4):711-5. doi: 10.1016/j.ymgme.2012.10.018. Epub 2012 Oct 24. Mol Genet Metab. 2012. PMID: 23146289

6

Enzyme replacement therapy in two Japanese siblings with Fabry disease, and its effectiveness on angiokeratoma and neuropathic pain.

Furujo M, Kubo T, Kobayashi M, Ohashi T. Furujo M, et al. Among authors: kobayashi m. Mol Genet Metab. 2013 Nov;110(3):405-10. doi: 10.1016/j.ymgme.2013.07.005. Epub 2013 Jul 14. Mol Genet Metab. 2013. PMID: 23906479

7

Characteristics of Cerebral Microbleeds in Patients with Fabry Disease.

Kono Y, Wakabayashi T, Kobayashi M, Ohashi T, Eto Y, Ida H, Iguchi Y. Kono Y, et al. Among authors: kobayashi m. J Stroke Cerebrovasc Dis. 2016 Jun;25(6):1320-5. doi: 10.1016/j.jstrokecerebrovasdis.2016.02.019. Epub 2016 Mar 14. J Stroke Cerebrovasc Dis. 2016. PMID: 26987491

8

Frequency of de novo mutations in Japanese patients with Fabry disease.

Kobayashi M, Ohashi T, Iizuka S, Kaneshiro E, Higuchi T, Eto Y, Ida H. Kobayashi M, et al. Mol Genet Metab Rep. 2014 Aug 2;1:283-287. doi: 10.1016/j.ymgmr.2014.07.001. eCollection 2014. Mol Genet Metab Rep. 2014. PMID: 27896102 Free PMC article.

9

The beneficial effects of long-term enzyme replacement therapy on cardiac involvement in Japanese Fabry patients.

Hongo K, Ito K, Date T, Anan I, Inoue Y, Morimoto S, Ogawa K, Kawai M, Kobayashi H, Kobayashi M, Ida H, Ohashi T, Taniguchi I, Yoshimura M, Eto Y. Hongo K, et al. Among authors: kobayashi h, kobayashi m. Mol Genet Metab. 2018 Jun;124(2):143-151. doi: 10.1016/j.ymgme.2018.04.008. Epub 2018 Apr 26. Mol Genet Metab. 2018. PMID: 29747997 Clinical Trial.

10

Mutation spectrum of α-Galactosidase gene in Japanese patients with Fabry disease.

Kobayashi M, Ohashi T, Kaneshiro E, Higuchi T, Ida H. Kobayashi M, et al. J Hum Genet. 2019 Jul;64(7):695-699. doi: 10.1038/s10038-019-0599-z. Epub 2019 Apr 15. J Hum Genet. 2019. PMID: 30988410

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

11,878 results

Search Page